Indoleamine 2,3-dioxygenase 1 promotes osteosarcoma progression by regulating tumor-derived exosomal miRNA hsa-miR-23a-3p
Background: Osteosarcoma (OS) is the most common primary malignant tumor originating in bone. Immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1) participates in tumor immune tolerance and promotes tumor progression, while the study of IDO1 in OS is limited.Methods: Immunohistochemistry an...
Main Authors: | Dan Yang, Yinxian Chen, Zhen Ning Tony He, Yichen Wang, Chenghui Ke, Yi Luo, Sun Wang, Qichao Ma, Mengjie Chen, Qing Yang, Ziming Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-05-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1194094/full |
Similar Items
-
Indoleamine 2,3- Dioxygenase: A Novel Immunotherapeutic Target for Osteosarcoma
by: Asim Farooq, et al.
Published: (2022-09-01) -
Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
by: Cemil Bilir, M.D., et al.
Published: (2017-07-01) -
TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
by: V. A. Kozlov, et al.
Published: (2017-07-01) -
Serum indoleamine 2,3-dioxygenase level and diagnostic value in patients with rosacea
by: Merve Sena Odabasi, et al.
Published: (2023-01-01) -
Comprehensive behavioral analysis of indoleamine 2,3‐dioxygenase knockout mice
by: Nao Hirata, et al.
Published: (2018-09-01)